McKesson jumps into a $5.8B deal spree

The pharmacy giant just went shopping

McKesson, private equity shop CD&R, and Option Care Health have signed a definitive agreement for a take-private style acquisition of OPCH at $32.05 per share. That tags the deal at roughly $5.8 billion enterprise value, which is a very fancy way of saying this isn’t a casual grocery run—it’s a full-on cart-filling spree.

Why you should care

For McKesson, this looks like a move to deepen its reach in the care-delivery and infusion-services world. If the deal closes, the company gets a bigger seat at the table in a health-care corner that’s less about pill bottles and more about where treatment actually happens.

For Option Care Health shareholders, the headline is simpler: cash-out value, and a premium that gives the stock a big potential re-rating if the market had been pricing in less.

The fine print that matters

• The parties say the agreement is definitive, so this is more than just deal chatter.
• The purchase price is $32.05 per share.
• The implied enterprise value is about $5.8 billion.

The usual deal caveats still apply: financing, regulatory review, and closing conditions can always throw a banana peel in front of the parade.

Big picture: McKesson isn’t just distributing medicine here—it’s trying to own more of the patient journey. And in health care, that can be the difference between being the middleman and being the platform.